Search details
1.
Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes.
Haemophilia
; 27(5): 751-759, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34160870
2.
An overview of inherited factor VII deficiency.
Transfus Apher Sci
; 58(5): 569-571, 2019 Oct.
Article
in English
| MEDLINE | ID: mdl-31447397
3.
The impact of extended half-life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B.
Res Pract Thromb Haemost
; 5(7): e12601, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34667922
4.
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Leuk Lymphoma
; 47(4): 697-706, 2006 Apr.
Article
in English
| MEDLINE | ID: mdl-16690529
5.
Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial.
J Clin Oncol
; 33(17): 1936-42, 2015 Jun 10.
Article
in English
| MEDLINE | ID: mdl-25897153
6.
Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty.
J Bone Joint Surg Am
; 84(11): 1992-7, 2002 Nov.
Article
in English
| MEDLINE | ID: mdl-12429760
7.
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.
Cancer
; 116(1): 106-14, 2010 Jan 01.
Article
in English
| MEDLINE | ID: mdl-19890959
8.
Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
J Clin Oncol
; 26(27): 4473-9, 2008 Sep 20.
Article
in English
| MEDLINE | ID: mdl-18626004
9.
Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
J Clin Oncol
; 26(2): 204-10, 2008 Jan 10.
Article
in English
| MEDLINE | ID: mdl-18182663
Results
1 -
9
de 9
1
Next >
>>